ART Announces First Sale of SoftScan Optical Breast Imaging System
February 20 2008 - 11:26AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce
the first sale of its SoftScan� optical breast imaging system to
the Sunnybrook Health Sciences Centre ('Sunnybrook") in Toronto,
Canada. Sunnybrook is the first health centre to purchase a
SoftScan imaging system since ART received regulatory approval from
Health Canada for the commercialization of its optical breast
imaging device.
Dr. Gregory Czarnota, Radiation Oncologist at Odette Cancer
Centre, Sunnybrook Health Sciences Centre, and Scientist in Imaging
Research at Sunnybrook Research Institute, is the principal
investigator of a pilot study to determine the role for the
SoftScan system in monitoring response to treatment of breast
cancer, particularly neoadjuvant therapies. He works with Dr.
Martin Yaffe, Senior Scientist in Imaging Research at Sunnybrook
Research Institute, in advancing this programme. Dr. Czarnota
commented: "We are very encouraged by the results obtained so far
with the SoftScan system, which offers us an objective method of
measuring treatment response to breast cancer. Medical oncologists
such as myself want to quantify, to put a number on what's
occurring. SoftScan enables them to do this because it can identify
tumours by their metabolic signatures."
"We are proud to partner with Dr. Czarnota, Dr. Yaffe, and their
team at Sunnybrook as they conduct ground-breaking research into
breast cancer treatment monitoring," said Sebastien Gignac, ART's
President and CEO. "The SoftScan imaging system's ability to
provide highly-sensitive functional information on the evolution of
cancer lesions allows ART to contribute to the development of
personalized medicine and help maximize the efficacy of therapies
for women with breast cancer", concluded Mr. Gignac.
About the SoftScan� system
The SoftScan � optical breast imaging system has been designed
first as a complementary diagnostic tool to mammography, with
ultimate uses in the detection and treatment monitoring of breast
cancer. Its non-invasive, painless approach uses time-domain
optical imaging technology, which may allow clinicians to better
locate and characterize breast tumors as benign or malignant and
could provide faster assessment of therapeutic effectiveness.
Unlike mammography whose use must be strictly limited, the SoftScan
system emits no radiation and can be safely used as often as needed
to monitor patients. The device was created and developed by ART
Advanced Research Technologies Inc., and has obtained regulatory
approvals for its commercialization in Canada and in Europe.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan� optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
these products in a global strategic alliance with GE Healthcare, a
world leader in mammography and imaging. Finally, the Fenestra�
line of molecular imaging contrast products provide image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART's
shares are listed on the TSX under the ticker symbol ARA. For more
information on ART, visit our website at www.art.ca .
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca Dr. Joseph
Kozikowski Chief Medical Officer 514-832-0777 jkozikowski@art.ca
www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024